Ionis to hold olezarsen Phase 3 data webcast
Webcast scheduled for Monday, April 8 at 10:00 a.m. Eastern Time CARLSBAD, Calif. , March 28, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live...
View ArticleIonis presents positive results from Phase 3 Balance study of olezarsen for...
– Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events – –...
View ArticleIonis to hold first quarter 2024 financial results webcast
Webcast scheduled for Tuesday, May 7 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , April 23, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live...
View ArticleIonis Publishes 2023 Corporate Responsibility Report
Established new corporate responsibility strategic pillars and actionable goals Received approval for two Ionis-discovered medicines in 2023, and continued to advance a broad pipeline poised to bring a...
View ArticleIonis reports first quarter 2024 financial results
WAINUA TM launch on track; EU and Canada approval decisions expected this year Olezarsen NDA submitted to FDA for FCS ; preparing EU regulatory submission Positive Phase 3 donidalorsen data for HAE;...
View ArticleIonis to host 2024 virtual Annual Meeting of Stockholders
CARLSBAD, Calif. , May 15, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a...
View ArticleIonis announces positive topline results from Phase 1/2a trial of ION582 for...
ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients ION582 was safe and well tolerated at all dose levels Ionis plans to move ION582 into...
View ArticleIonis and Biogen Announce Topline Phase 1/2 Study Results of Investigational...
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis...
View ArticleNew data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™...
– Results across NEURO-TTRansform subgroups show consistent benefit in neuropathy impairment and improved quality of life, regardless of patient segmentation – CARLSBAD, Calif. , May 23, 2024...
View ArticleIonis to hold donidalorsen Phase 3 data webcast
Webcast scheduled for Friday, May 31 at 8:00 a.m. Eastern Time CARLSBAD, Calif. , May 28, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast...
View ArticleIonis presents positive results from OASIS-HAE and OASISplus studies of...
Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing;...
View ArticleIonis presents positive results from Phase 3 Balance study of olezarsen for...
– Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events – –...
View ArticleIonis to hold first quarter 2024 financial results webcast
Webcast scheduled for Tuesday, May 7 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , April 23, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live...
View ArticleIonis Publishes 2023 Corporate Responsibility Report
Established new corporate responsibility strategic pillars and actionable goals Received approval for two Ionis-discovered medicines in 2023, and continued to advance a broad pipeline poised to bring a...
View ArticleIonis reports first quarter 2024 financial results
WAINUA TM launch on track; EU and Canada approval decisions expected this year Olezarsen NDA submitted to FDA for FCS ; preparing EU regulatory submission Positive Phase 3 donidalorsen data for HAE;...
View ArticleIonis to host 2024 virtual Annual Meeting of Stockholders
CARLSBAD, Calif. , May 15, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a...
View ArticleIonis announces positive topline results from Phase 1/2a trial of ION582 for...
ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients ION582 was safe and well tolerated at all dose levels Ionis plans to move ION582 into...
View ArticleIonis and Biogen Announce Topline Phase 1/2 Study Results of Investigational...
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis...
View ArticleNew data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™...
– Results across NEURO-TTRansform subgroups show consistent benefit in neuropathy impairment and improved quality of life, regardless of patient segmentation – CARLSBAD, Calif. , May 23, 2024...
View ArticleIonis to hold donidalorsen Phase 3 data webcast
Webcast scheduled for Friday, May 31 at 8:00 a.m. Eastern Time CARLSBAD, Calif. , May 28, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast...
View Article